New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2013
07:48 EDTPTXPernix Therapeutics shares could rebound on good execution, says Stifel
After Pernix reported much lower than expected Q1 revenue, Stifel lowered its price target on the stock to $4 from $10 but keeps a Buy rating on the shares based on valuation.
News For PTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 20, 2015
08:31 EDTPTXPernix Therapeutics sees Q4 net revenue in excess of $52M, consensus $46.26M
08:31 EDTPTXPernix Therapeutics sees FY14 net revenue in excess of $120M, consensus $114.16M
Subscribe for More Information
January 15, 2015
15:45 EDTPTXPernix Therapeutics announces sNDA for Treximet accepted by FDA
Pernix Therapeutics Holdings announced that its supplemental New Drug Application, sNDA, for Treximet has been accepted by the FDA. Approval is expected in 2Q 2015, based on the anticipated Prescription Drug User Fee Act, PDUFA, action date. The company’s sNDA, submitted on November 14 seeks approval for Treximet for use in adolescent patients, age 12–17, for the acute treatment of migraine with or without aura. Included in the filing are safety and efficacy data sets from three trials conducted to evaluate the pharmacokinetic, efficacy, and long-term safety of Treximet for the acute treatment of adolescent migraine. To date, there is no sumatriptan or combination prescription medication for the treatment of acute migraine attacks with or without aura approved for use in this population. Presently, Treximet is approved in the U.S. for the acute treatment of migraine with or without aura in adults.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use